ESMO 2025 | Optimal sequencing of trastuzumab deruxtecan in HER2+ breast cancer
Jean-Yves Pierga, MD, Institut Curie, Paris, France, highlights the evolving role of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer, noting its routine use in the second line. Following results from the DESTINY-Breast09 trial (NCT04784715), there is also potential for first-line use. Clinicians should additionally consider long-term tolerance and maintenance treatment for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So now in real life, an indication of T-DXd in HER-positive metastatic breast cancer has changed and now we are using it routinely in the second line, not for more than two or three lines. And then there’s a question right now, according to the DC09 result presented at the ASCO, should we use it even in the first line for this population? But then the matter of tolerance on the long term and the maintenance treatment is clearly the question for this patient...
So now in real life, an indication of T-DXd in HER-positive metastatic breast cancer has changed and now we are using it routinely in the second line, not for more than two or three lines. And then there’s a question right now, according to the DC09 result presented at the ASCO, should we use it even in the first line for this population? But then the matter of tolerance on the long term and the maintenance treatment is clearly the question for this patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
